Inventor
KAMIYA TAKAHIRO
JP19 patents
⚠️ This page may combine multiple inventors who share the name “KAMIYA TAKAHIRO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NAT UNIV SINGAPORE
11 patentsUS11896616B2Feb 13, 2024
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
NAT UNIV SINGAPORE7 citations85
US11679132B2Jun 20, 2023
Methods for enhancing efficacy of therapeutic immune cells
NAT UNIV SINGAPORE5 citations85
US11648269B2May 16, 2023
T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
NAT UNIV SINGAPORE6 citations85
US10765699B2Sep 8, 2020
Methods for enhancing efficacy of therapeutic immune cells
NAT UNIV SINGAPORE8 citations84
US11440958B2Sep 13, 2022
Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
NAT UNIV SINGAPORE8 citations83
US10550183B2Feb 4, 2020
Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
NAT UNIV SINGAPORE11 citations83
US11945865B2Apr 2, 2024
Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
NAT UNIV SINGAPORE3 citations72
US12479914B2Nov 25, 2025
T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
NAT UNIV SINGAPORE0 citations62
US12404492B2Sep 2, 2025
Methods for enhancing efficacy of therapeutic immune cells
NAT UNIV SINGAPORE0 citations62
US12404491B2Sep 2, 2025
Methods for enhancing efficacy of therapeutic immune cells
NAT UNIV SINGAPORE0 citations62
US12129485B2Oct 29, 2024
Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies
NAT UNIV SINGAPORE0 citations60